Nektar Therapeutics (NKTR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Nektar Therapeutics reported revenue of $55.2M, down 43.9% from $98.4M the year before. Net income was -$164.1M (a -297.1% net margin), or -$9.73 per diluted share. Gross margin was 100.0% and operating margin was -253.7%. Operating activities generated -$208.5M of cash, leaving -$208.7M of free cash flow. At fiscal year end, Nektar Therapeutics held $280.4M in total assets against $190.6M in total liabilities, including $15.1M of cash and equivalents.
Open the full interactive Nektar Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Nektar Therapeutics Key Stats
| Share Price | $37.92 |
|---|---|
| Market Cap | $1.25B |
| Revenue YoY Growth | -43.9% |
| 52-Week Range | $35.12 – $100.35 |
| Shares Outstanding | 33.1 million (basic, 2026 Q2) |
Nektar Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $152.9M | $101.9M | $92.1M | $90.1M | $98.4M | $55.2M |
| Cost of Goods Sold | $19.5M | $24.9M | $21.6M | $33.8M | $30.7M | $0 |
| Gross Profit | $133.4M | $77.0M | $70.4M | $56.4M | $67.7M | $55.2M |
| Operating Income | -$425.1M | -$446.1M | -$376.2M | -$263.7M | -$105.2M | -$140.1M |
| Pre-Tax Income | -$443.9M | -$523.3M | -$365.0M | -$276.3M | -$119.2M | -$155.5M |
| Income Tax | $493,000 | $557,000 | $3.2M | -$200,000 | -$239,000 | -$138,000 |
| Net Income | -$444.4M | -$523.8M | -$368.2M | -$276.1M | -$119.0M | -$164.1M |
| Diluted EPS | -$37.35 | -$42.90 | -$29.55 | -$21.75 | -$8.70 | -$9.73 |
Nektar Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $11.8M | $21.8M | $10.9M | $10.1M |
| Net Income | -$35.5M | -$36.1M | -$44.9M | -$40.6M |
| Diluted EPS | -$1.87 | -$2.14 | -$1.82 | -$1.23 |
Nektar Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $199.0M | $25.2M | $88.2M | $35.3M | $44.3M | $15.1M |
| Current Assets | $1.14B | $795.6M | $546.0M | $330.7M | $261.3M | $266.3M |
| Total Assets | $1.54B | $1.12B | $710.6M | $398.0M | $303.9M | $280.4M |
| Current Liabilities | $115.8M | $85.2M | $68.2M | $51.3M | $61.4M | $53.5M |
| Total Liabilities | $461.5M | $437.7M | $344.0M | $267.0M | $243.1M | $190.6M |
| Shareholders' Equity | $1.08B | $679.5M | $366.6M | $131.0M | $60.7M | $89.8M |
Nektar Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$313.3M | -$412.7M | -$304.0M | -$192.6M | -$175.7M | -$208.5M |
| Cash From Investing | $496.2M | $202.8M | $365.8M | $139.6M | $142.6M | -$1.2M |
| Cash From Financing | -$80.4M | $36.2M | $1.5M | $30,000 | $42.1M | $180.6M |
| Free Cash Flow | -$320.5M | -$427.6M | -$309.7M | -$193.5M | -$177.2M | -$208.7M |
Figures from Nektar Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Nektar Therapeutics financials page for every line item.
Nektar Therapeutics Company Profile
| Ticker | NKTR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000906709 |
Frequently Asked Questions
What was Nektar Therapeutics' revenue in fiscal 2025?
Nektar Therapeutics (NKTR) reported revenue of $55.2M for fiscal 2025.
What is Nektar Therapeutics' annual revenue history?
Nektar Therapeutics' annual revenue by fiscal year: 2020: $152.9M; 2021: $101.9M; 2022: $92.1M; 2023: $90.1M; 2024: $98.4M; 2025: $55.2M.
What was Nektar Therapeutics' net income in fiscal 2025?
Nektar Therapeutics reported net income of -$164.1M for fiscal 2025.
What was Nektar Therapeutics' earnings per share (EPS) in fiscal 2025?
Nektar Therapeutics' diluted EPS was -$9.73 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Nektar Therapeutics generate in fiscal 2025?
Nektar Therapeutics generated -$208.7M of free cash flow in fiscal 2025.
What was Nektar Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Nektar Therapeutics reported revenue of $10.1M.
How many shares of Nektar Therapeutics are outstanding?
Nektar Therapeutics reported a weighted average of 33.1 million basic shares outstanding in 2026 Q2.
What is Nektar Therapeutics' market cap?
Based on its latest closing price, Nektar Therapeutics (NKTR) has a market capitalization of about $1.25B.
When does Nektar Therapeutics' fiscal year end?
Nektar Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Nektar Therapeutics headquartered?
Nektar Therapeutics lists its business address in San Francisco, California in its SEC filings.